SRGAP3 has been implicated as a potential oncogenic driver in low-grade gliomas, when fused with RAF1, resulting in constitutive activation of the ERK/MAPK pathway [21, 44], and altered expression of the SRGAP protein has been demonstrated in breast cancer [41]. This evidence concerns the gene RAF1 and glioma.